Chief Medical Officer, Christopher Wright, MD, PhD, is a neurologist and neuroscientist who brings two decades of medical research and drug development experience in orphan and specialty diseases, including cystic fibrosis, dementia, hepatitis C, rheumatoid arthritis, and epilepsy. While at Vertex, Dr. Wright oversaw the development of ORKAMBI® through Phase 3, and the successful development and rapid approval of KALYDECO®, a lifechanging cystic fibrosis therapy, by the FDA, EMA and other health authorities. He also played an important role in the global development and approval of INCIVEK® for hepatitis C. Prior to joining our team, Dr. Wright led the global development organization at Ironwood, including responsibility for advancing the late stage and lifecycle gastrointestinal and sGC programs. Dr. Wright was an Associate Professor of Neurology at Harvard Medical School and practiced neurology at Brigham and Women’s Hospital in Boston, MA for 20 years.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related